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Abstract
Background: Rotavirus causes severe gastroenteritis in infants and young children worldwide. The UK introduced
the monovalent rotavirus vaccine (Rotarix®) in July 2013. Vaccination is free of charge to parents, with two doses
delivered at 8 and 12 weeks of age. We evaluated vaccine impact across a health system in relation to
socioeconomic deprivation.
Methods: We used interrupted time-series analyses to assess changes in monthly health-care attendances in
Merseyside, UK, for all ages, from July 2013 to June 2016, compared to predicted counterfactual attendances without
vaccination spanning 3–11 years pre-vaccine. Outcome measures included laboratory-confirmed rotavirus gastroenteritis
(RVGE) hospitalisations, acute gastroenteritis (AGE) hospitalisations, emergency department (ED) attendances for
gastrointestinal conditions and consultations for infectious gastroenteritis at community walk-in centres (WIC) and
general practices (GP). All analyses were stratified by age. Hospitalisations were additionally stratified by vaccine uptake
and small-area-level socioeconomic deprivation.
Results: The uptake of the first and second doses of rotavirus vaccine was 91.4% (29,108/31,836) and 86.7%
(27,594/31,836), respectively. Among children aged < 5 years, the incidence of gastrointestinal disease decreased across
all outcomes post-vaccine introduction: 80% (95% confidence interval [CI] 70–87%; p < 0.001) for RVGE hospitalisation,
44% (95% CI 35–53%; p < 0.001) for AGE hospitalisations, 23% (95% CI 11–33%; p < 0.001) for ED, 32% (95% CI 7–50%;
p = 0.02) for WIC and 13% (95% CI -3–26%; p = 0.10) for GP. The impact was greatest during the rotavirus season and for
vaccine-eligible age groups. In adults aged 65+ years, AGE hospitalisations fell by 25% (95% CI 19–30%; p < 0.001).
The pre-vaccine risk of AGE hospitalisation was highest in the most socioeconomically deprived communities (adjusted
incident rate ratio 1.57; 95% CI 1.51–1.64; p < 0.001), as was the risk for non-vaccination (adjusted risk ratio 1.54; 95%
CI 1.34–1.75; p < 0.001). The rate of AGE hospitalisations averted per 1,000 first doses of vaccine was higher among infants
in the most deprived communities compared to the least deprived in 2014/15 (28; 95% CI 25–31 vs. 15; 95% CI 12–17)
and in 2015/16 (26; 95% CI 23–30 vs. 13; 95% CI 11–16).
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Conclusions: Following the introduction of rotavirus vaccination, incidence of gastrointestinal disease reduced across the
health-care system. Vaccine impact was greatest among the most deprived populations, despite lower vaccine uptake.
Prioritising vaccine uptake in socioeconomically deprived communities should give the greatest health benefit
in terms of population disease burden.
Keywords: Surveillance, Rotavirus, Vaccine, Gastroenteritis, Paediatric, Diarrhoea, Health equity, Socioeconomic
inequalities, Health service, Epidemiology
Background
Prior to the introduction of rotavirus vaccination, rota-
virus was the leading cause of severe gastroenteritis in
children under 5 years of age worldwide, resulting in ap-
proximately 453,000 deaths per year and 40% of diarrhoeal
hospital admissions [1, 2]. Two orally administered live-
attenuated rotavirus vaccines, Rotarix® (GlaxoSmithKline
Biologicals, Belgium) and RotaTeq® (Merck Vaccines,
USA), have been introduced in over 90 countries world-
wide [3]. The global mortality from rotavirus gastroenter-
itis (RVGE) has subsequently more than halved (recently
estimated at between ~120,000 and ~215,000) and the
number of all-cause acute gastroenteritis (AGE) hospitali-
sations is estimated to have reduced by 38% [4–7].
Although the majority of the severe disease burden is in
developing countries, rotavirus was estimated to cause ap-
proximately 80,000 general practice (GP) consultations
and 750,000 diarrhoea episodes each year in the UK [8];
45% of hospitalisations and 20% of emergency department
(ED) attendances for AGE in children under 5 years of age
were attributable to rotavirus [9]. The National Health
Service (NHS) in England is free at the point of use for all
UK residents, with vaccinations included in the routine
immunisation schedule also free of charge. The monova-
lent rotavirus vaccine (Rotarix®) was introduced into the
UK childhood immunisation schedule in July 2013, with
two doses delivered at 8 and 12 weeks of age [10]. Vaccine
uptake in England increased rapidly, reaching over 91%
for one dose by February 2014 and over 94% by mid-2016
[11]. To date, studies in the UK have separately, and for
varied populations and time periods, analysed vaccine im-
pact on rotavirus laboratory detections (77% reduction in
infants) [12], RVGE hospitalisations (> 80% reduction in
infants) [13], all-cause AGE hospitalisations (26% in in-
fants) [12] and GP attendances for diarrhoea related ill-
ness (20–30% in those under 5 years old) [14].
This study aimed to assess the effect of rotavirus vac-
cination on multiple levels of the UK health-care system
simultaneously, by examining the trends in hospitalisa-
tions, ED attendances, community health consultations
and GP consultations for outcomes of gastroenteritis,
diarrhoea and rotavirus gastroenteritis in a defined
population before and after vaccine introduction. This
approach will, for the first time, provide estimates of
rotavirus vaccine impact in an entire health economy.
Secondly, within the UK, children under 5 years of age
are over-represented in the most socioeconomically de-
prived populations [15, 16], and experience significantly
higher incidence of all-cause AGE hospitalisations than
more affluent populations [17]. It is known that in the
UK, the uptake of routine childhood vaccines (e.g.
vaccines for measles, mumps and rubella, human
papillomavirus and influenza) is lower in socioeconomi-
cally deprived populations [18–20]. Thus, we examined
the uptake and impact of rotavirus vaccination in
Merseyside, an area with a wide variation in socioeco-
nomic deprivation, to assess whether vaccine uptake
and impact are equitable.
Methods
Study setting
The study population was the metropolitan area of
Merseyside, England, with an estimated resident popula-
tion of 1.4 million and an annual birth cohort of ap-
proximately 16,000. In 2016, 80,000 of the population
were under 5 years of age [16]. Merseyside contains five
local authorities (Knowsley, Liverpool, Sefton, St Helens
and Wirral), containing multiple NHS trusts and organi-
sations. Health-care for the population is provided in the
community by GP practices and walk-in centres (WICs),
offering both primary and urgent care. There are five
hospitals with emergency and secondary-care facilities,
including a large paediatric hospital (Alder Hey
Children’s NHS Foundation Trust). The organisations
and facilities have been previously described [21].
Data sources and case definitions for outcome measures
Data sources and full case definitions have been previ-
ously published [21]. Table 1 summarises these details,
and amends any discrepancies. Notably, data on GP con-
sultations were obtained through the NHS clinical
commissioning groups (CCGs). Coding for non-
infectious gastroenteritis (ICD-10 K52.9) was included in
the all-cause AGE hospitalisation outcome measure,
since unspecified gastroenteritis was classified under this
code until April 2012 [22].
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Area of residence and socioeconomic deprivation
In each of the health data sets accessed, an indicator for
neighbourhood area of residence (lower super output
area [LSOA]) was included. English LSOAs are small
statistical boundaries defined following the 2001 and
2011 censuses and consist of approximately 1,500
people. A standardised measure of socioeconomic
deprivation was assigned to each participant, using the
LSOA of their residence and the English indices of
deprivation 2015, the Index of Multiple Deprivation
(IMD) [15]. The English indices of deprivation are pro-
duced and quality controlled using national census and
other administrative data [15]. They are constructed
from 37 robust indicators in seven domains: education
skills and training, employment, income, living environ-
ment, crime, and barriers to housing and other services
[15]. These domains are combined and weighted to
calculate one of the most robust and commonly used
measures of deprivation in England, the IMD [15, 18].
Uptake of rotavirus vaccination
Pseudo-anonymised vaccine status data were extracted
from the Child Health Information Service (CHIS)
[23, 24], which is managed locally by NHS trusts and
holds a unique record for each child born in these
areas until the age of 18 years. We obtained a CHIS
data extract on children eligible for rotavirus vaccin-
ation born from May 2013 to June 2016. The extract
included a unique identifier, year and month of birth,
year and month of first and second doses of rotavirus vac-
cine, and LSOA of residence. CHIS could be accessed for
four out of the five local authorities in Merseyside. Data
for Wirral could not be extracted due to the lack of access
to the CHIS database during the study period, which was
Table 1 Details of each outcome measure and data source
Data source Population Outcome Denominator/offset Age in months
(m) or years (y)
Time period
Alder Hey Children's
NHS Foundation
Trust
RVGE hospitalisations.
Alder Hey's footprint
covers the majority
of Merseyside children
Laboratory-confirmed rotavirus
gastroenteritis. Rotavirus antigen
detected by
immunochromatography test
(2005–2009) or by enzyme
immunoassay
(2002–2005 and 2009 onwards)
in a faecal specimen of a child
with acute gastroenteritis
Total hospitalisations per
month by age group
0–14 y: < 12 m;
12–23 m;
24–59 m;
5–14 y
July 2002 to
June 2016
Hospital Episode
Statistics –
admitted
patient care
Merseyside residents
attending any
hospital in England
Hospitalisation for all-cause acute
gastroenteritis. Identified by ICD-10
codes: A00–A09) or as
non-infectious gastroenteritis
(K52.9), in any
diagnosis field
Yearly estimated age-specific
population of Merseyside.
Source: Office for National
Statistics; accessed through
Public Health England [16]
All ages: < 12 m;
12–23 m;
24–59 m;
5–14 y;
15–64 y;
65+
July 2000 to
June 2016
Hospital Episode Statistics –
accident and
emergency
Merseyside residents
attending three
major emergency
departments in
Merseyside
Emergency department attendance
for gastrointestinal conditions
(AE diagnosis code 26); excluding
subsequent admissions. Missing
diagnosis data was imputed for
one emergency department
between November 2010
and March 2011
Total emergency
department attendances
(excluding subsequent
admissions) per month
by age group
All ages: < 12 m;
12–23 m;
24–59 m;
5–14 y;
15–64 y; 65+
July 2008 to
June 2016
Walk-in centre
attendance
records
Attendances at walk-in
centres in Wirral,
covering an estimated
resident population
of 320,000
Walk-in centre attendance for
infectious gastroenteritis. Read
Codes: gastroenteritis – presumed
infectious origin (A0812), diarrhoea
of presumed infectious origin (A083);
infantile viral gastroenteritis (A07y1);
infectious gastroenteritis (A0803);
enteritis due to rotavirus (A0762);
and infectious diarrhoea (A082)
All walk-in centre
attendances per month
by age group
All ages: < 12 m;
12–23 m;
24–59 m;
5–14 y;
15–64 y;
65+
July 2011 to
June 2016
GP records Consultations at
136 GP practices in
Merseyside, covering
an estimated
population of
790,000
Consultations for infectious
gastroenteritis
(Read Codes as above
for walk-in centre)
Yearly estimated GP
registered population by
age group. Data were available
from 2010 to 2016, therefore
estimates for 2007/2008 and
2008/2009 were synthetically
estimated using predictions
from linear regression models.
Source: Public Health England
and participating GP practices
All ages: < 12 m;
12–23 m;
24–59 m;
5–14 y;
15–64 y; 65+
July 2007 to
June 2016
GP general practice, RVGE rotavirus gastroenteritis, AE accident and emergency
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related to organisational restructuring. We used codes in
the CHIS data set to exclude from the analysis deaths,
stillbirths and children who were born in Merseyside
during the study period but subsequently moved out.
Statistical analyses
Impact
We examined monthly hospitalisations and attendances
to health-care providers using an interrupted time-series
design. Firstly, to predict counterfactual numbers of hos-
pitalisations and attendances that would have been ex-
pected in the absence of vaccination for the vaccine
period, we fitted generalised linear models with Poisson
or negative binomial distributions (to account for over-
dispersion in the data) to pre-vaccine introduction
monthly counts, offset for a data-set-specific denomin-
ator (Table 1). We adjusted for seasonal trends by in-
cluding a categorical term for calendar month and
secular trends by including a linear term for surveillance
year (July to June) as explanatory variables in the
models. Secondly, to quantify the percentage reduction
in monthly attendances and hospitalisations, we in-
cluded all data pre- and post-vaccine introduction in a
second model with a binary indicator variable denoting
the post-vaccine period. This second model also in-
cluded the same terms to adjust for seasonal and secular
trends and allowed the calculation of incidence rate ra-
tios (IRRs). The percentage reduction was calculated as
100 1  IRRð Þ . The RVGE season in the UK in the
pre-vaccine period was consistently between the months
of January and May with the peak occurring in early to
mid-March in most years [25]. For the sensitivity ana-
lysis, we examined the specificity of the end point by
stratifying by events that occurred in-season (January to
May) and out-of-season (June to December). To investi-
gate vaccine impact by age, the analysis was stratified by
age group (< 12 months, 12–23 months, 24–59 months,
5–14 years, 15–64 years, 65+ years and 0–59 months).
Socioeconomic deprivation, vaccine uptake and
hospitalisations
Firstly, we wished to assess whether the incidence of all-
cause AGE hospitalisations varied by level of socioeco-
nomic deprivation. To achieve this, we fitted negative
binomial generalised linear models with the number of
hospitalisations as the dependent variable and the quintile
of deprivation as the independent variable, offset for
population denominator and adjusting again for seasonal
and secular trends. The quintile of deprivation was calcu-
lated using the IMD scores for LSOAs nationally, whereby
quintile 5 is the least deprived and quintile 1 the most
deprived. Since the population of Merseyside is skewed
towards the most deprived national quintiles (45% of the
population are in the most deprived quintile and 8% in
the least deprived), we combined the two least deprived
quintiles into category 4/5 (least deprived). All-cause AGE
hospitalisations were included in the model for the time
period July 2004 to June 2016 because LSOA information
was not available prior to April 2004. The models allowed
the calculation of IRR for socioeconomic deprivation
groups by comparing the 4/5 least deprived category to
the other quintiles, stratified by age group.
Secondly, we describe the uptake of the first and sec-
ond doses of rotavirus vaccine by month of birth for
children born between May 2013 and December 2015.
December 2015 was selected as the cut-off to allow all
children in the cohort to reach 25 weeks of age, the
upper time limit for rotavirus vaccination [26]. To inves-
tigate associations between socioeconomic deprivation
and vaccine uptake, we fitted logistic regression models
where the dependent variable was vaccine status and the
independent variable was the national quintile of IMD
and adjusted for gender and year and month of birth.
The models allowed the calculation of risk ratios (RRs)
for socioeconomic deprivation group by comparing the
4/5 least deprived category to the other quintiles.
Finally, we estimated the all-cause AGE hospitalisa-
tions averted per 1,000 vaccine first doses delivered in
the 2014/15 and 2015/16 seasons for vaccine-eligible co-
horts aged < 12 months and 12–23 months. We define
the rate of hospitalisations averted per 1,000 vaccine first
doses delivered as:
RDAijk ¼ Xijk−Y ijkPijkV ijk
where RDA is the rate of hospitalisations averted per
1,000 vaccine first doses delivered. X is the model-pre-
dicted counterfactual number of hospitalisations that
would have been expected in the absence of vaccination
for the vaccine period. Y is the observed number of hospi-
talisations in the vaccine period, P the population denom-
inator,V the proportion of the population vaccinated with
one dose of rotavirus vaccine, i the deprivation group, j
the age group and k the surveillance year.
We used the RDA in the Merseyside population in this
study to provide an estimate of the number of all-cause
AGE hospitalisations averted at a national level if the 95%
vaccine uptake targets set by the World Health
Organization (WHO) were achieved across all deprivation
strata [27, 28]. We define the total number of all-cause
AGE hospitalisations averted at a national level in 2015/16
at uniform 95% uptake as:
NDA ¼
XRDAijk
1000
 ðNijk  0:95Þ
where NDA is the number of all-cause AGE hospitalisa-
tions averted. RDA is the rate of hospitalisations averted
Hungerford et al. BMC Medicine  (2018) 16:10 Page 4 of 14
per 1,000 vaccine first doses delivered in the Merseyside
population. N is the national population denominator,
derived from mid-year LSOA population estimates
2015/16 [16]. i is the deprivation group, j is the age
group and k is the surveillance year.
Data handling and analysis were conducted in R ver-
sion 3.3 (R Development Core Team, Vienna, Austria).
Results
Vaccine uptake
Rotavirus vaccine uptake (at least one dose of vaccine)
in children born between May 2013 and December
2015 was 91.4% (29,108/31,836) and completion of the
full rotavirus vaccine schedule (i.e. two doses) was
86.7% (27,594/31,836). In the least deprived population,
vaccine uptake for at least one dose was 93.6% (4,135/
4,420) and 90.2% (3,989/4,420) for completion of the
two-dose schedule; in the most deprived population up-
take was 90.6% (16,550/18,259) and 84.9% (15,505/
18,259), respectively (Fig. 1). The most deprived popu-
lations had a 54% increased risk of non-vaccination
compared to the least deprived populations (RR 1.54;
95% CI 1.34–1.75). Furthermore, the most deprived
populations had almost twice the risk (RR 1.97; 95% CI
1.62–2.41) of non-completion of the two-dose schedule
compared to the least deprived.
Vaccine impact by age
Impact in those under 5 years old
In children less than 5 years of age, a clearly defined
rotavirus season was observed prior to vaccine introduc-
tion, with the peak predominately occurring in March
across all outcome measures for all years prior to vac-
cine introduction (Fig. 2). The incidence of gastrointes-
tinal disease fell across all health outcomes following
vaccine introduction (Fig. 2 and Table 2). The greatest
proportional reduction, 80% (95% CI 70–87%), was for
RVGE hospitalisation. All-cause AGE hospitalisations
fell by 44% (95% CI 35–53%), ED attendances for gastro-
intestinal conditions by 23% (95% CI 11–33%), and WIC
and GP consultations for infectious gastroenteritis by
32% (95% CI 7–50%) and 13% (95% CI -3–26%), respect-
ively. Reductions were greatest in the rotavirus season
for all outcomes. All-cause AGE hospitalisations fell by
58% (95% CI 45–67%) and GP consultations by 29%
(95% CI 8–45%).
Disease reductions were highest in vaccine-eligible
age groups. RVGE hospitalisation fell by 87% (95% CI
78–93%) in infants aged < 12 months and 84% (95%
CI 73–91%) in children 12–23 months. All-cause
AGE hospitalisations fell by 46% (95% CI 36–54%) in
infants < 12 months and 50% (95% CI 40–59%) in
children 12–23 months. For GPs, infectious gastro-
enteritis consultations fell by 19% (95% CI 4–33%) in
Fig. 1 Rotavirus vaccine uptake in 4/5 areas of Merseyside, UK, for children born between May 2013 and December 2015 by deprivation quintile
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infants, averting 136 consultations per 10,000 registered
population. There were also significant reductions in
gastrointestinal disease outcomes for vaccine-ineligible
children aged 24–59 months. RVGE hospitalisations
decreased in this age group by 66% (95% CI 44–81%)
and all-cause AGE hospitalisations decreased by 26%
(95% CI 11–39%). However, in the 2014/15 season, a
peak of incidence was detected in May across all pri-
mary outcome measures, which was comparable in
magnitude to the pre-vaccine rotavirus peak observed in
March. Disease rates by surveillance year and pre- and
post-vaccine introduction are provided in Additional
file 1: Table S1.
Impact in children aged 5 to 14 years
In the pre-vaccine period, children aged 5–14 years had
the lowest yearly rates of hospitalisation for all-cause
AGE (18 per 10,000 population) (Table 2). Rotavirus
seasonality in children aged 5–14 years was less pro-
nounced and inconsistent across all outcome mea-
sures in the pre-vaccine period (Fig. 2). In this
vaccine-ineligible age group, between July 2013 and
Fig. 2 Trends in five study outcome measures for children aged 0–14 years in Merseyside, UK, July 2008 to June 2016. Each analysis examines trends,
including a comparison of observed incidence (blue line) after rotavirus vaccination (July 2013 to June 2016) in the UK with expected incidence (red
line) and associated 95% confidence intervals (red shaded area) in the absence of vaccination. Expected incidence and 95% confidence intervals are
based on predictions from regression models fitted to available historic data for each outcome measure. The black hashed line represents the
introduction of rotavirus vaccine in the UK in July 2013. CI confidence interval, ED emergency department, GP general practice, WIC walk-in centre
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Table 2 Changes in rates of hospitalisation and attendances at different levels of the health system post-rotavirus vaccine introduction
in Merseyside, UK
Age group Mean yearly rate of hospitalisations and attendances (per 10,000)a Percentage reduction in hospitalisation and
attendance rates (95% CI)cPre-vaccination Post-vaccination
Observed Observed Expectedb Full year January–May June–December
Hospitalisations for laboratory-confirmed rotavirus to Alder Hey
< 12 m 129 14 122 87 (78 to 93) 94 (86 to 97) 57 (10 to 81)
12–23 m 123 16 106 84 (73 to 91) 87 (76 to 94) 70 (19 to 91)
24–59 m 33 10 29 66 (44 to 81) 74 (52 to 87) 35 (to 70 to 77)
5–14 y 7 0.3 9 95 (84 to 99) 96 (80 to 99.7) 94 (71 to 99.7)
Total 0–59 m 87 12 81 80 (70 to 87) 88 (80 to 94) 58 (25 to 77)
Hospitalisations for all-cause acute gastroenteritis
< 12 m 402 230 468 46 (36 to 54) 60 (49 to 69) 35 (20 to 46)
12–23 m 271 128 311 50 (40 to 59) 66 (56 to 74) 37 (19 to 50)
24–59 m 72 54 78 26 (11 to 39) 33 (10 to 50) 22 (1 to 38)
5–14 y 18 20 28 32 (21 to 41) 35 (19 to 48) 29 (13 to 42)
15–64 y 39 60 66 8 (2 to 14) 11 (1 to 19) 6 (1 to 13)
65+ 135 157 210 25 (19 to 30) 28 (19 to 36) 22 (15 to 29)
Total 0–59 m 178 104 213 44 (35 to 53) 58 (46 to 67) 35 (22 to 46)
ED attendances for gastrointestinal conditions (no admission)
< 12 m 2034 1855 2816 22 (11 to 33) 30 (15 to 42) 16 (2 to 29)
12–23 m 1146 892 1650 31 (15 to 43) 41 (19 to 57) 23 (4 to 38)
24–59 m 759 759 1054 12 (-4 to 25) 14 (-15 to 36) 10 (-6 to 24)
5–14 y 552 661 1038 22 (11 to 31) 17 (-2 to 33) 25 (12 to 36)
15–64 y 405 503 993 29 (16 to 40) 30 (4 to 49) 28 (14 to 40)
65+ 341 438 788 21 (4 to 34) 25 (-5 to 46) 18 (-3 to 34)
Total 0–59 m 1235 1124 1795 23 (11 to 33) 31 (12 to 45) 18 (4 to 29)
Walk-in centre attendances for infectious gastroenteritis
< 12 m 574 373 644 37 (6 to 58) 51 (12 to 73) 25 (-26 to 55)
12–23 m 463 256 606 39 (0 to 63) 67 (38 to 83) 5 (-86 to 52)
24–59 m 196 153 167 18 (-20 to 44) 36 (-12 to 64) -5 (-79 to 38)
5–14 y 79 71 68 0 (-52 to 34) 6 (-77 to 49) -6 (-86 to 39)
15–64 y 55 51 61 24 (7 to 38) 29 (0 to 49) 21 (-4 to 40)
65+ 22 18 52 47 (-15 to 75) 56 (-43 to 86) 38 (-72 to 78)
Total 0–59 m 362 231 363 32 (7 to 50) 51 (22 to 69) 12 (-27 to 39)
GP consultations for infectious gastroenteritis
< 12 m 674 492 628 19 (4 to 33) 40 (27 to 51) 3 (-20 to 21)
12–23 m 590 418 498 13 (-10 to 31) 38 (11 to 56) -11 (-44 to 14)
24–59 m 184 166 172 8 (-14 to 26) 7 (-29 to 33) 9 (-20 to 31)
5–14 y 53 56 51 -3 (-21 to 12) -7 (-38 to 17) 0 (-23 to 19)
15–64 y 41 30 41 26 (18 to 33) 29 (17 to 40) 23 (13 to 32)
65+ 35 29 48 36 (25 to 45) 43 (30 to 54) 30 (13 to 43)
Total 0–59 m 363 282 331 13 (-3 to 26) 29 (8 to 45) 0 (-20 to 17)
CI confidence interval, ED emergency department, GP general practice
aTable 1 provides specific denominators for each outcome measure
bExpected in the absence of vaccination using a negative binomial or Poisson model adjusting for month and rotavirus year for the pre-vaccine years
cPercentage change is calculated as 1-IRR. Incidence rate ratio (IRR) was calculated using a negative binomial model or Poisson model adjusting for month and
rotavirus year
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June 2016 there were only two laboratory-confirmed
detections of RVGE at Alder Hey Children’s Hospital.
Furthermore, all-cause AGE hospitalisations and ED
attendances for gastrointestinal conditions also fell
(Table 2). GP consultations (-3%, 95% CI -21–12%)
and WIC attendances (0%, 95% CI -52–34%) for infec-
tious gastroenteritis remained similar to pre-vaccine
levels. There were no differences between changes in
incidence in the rotavirus season and out of the rota-
virus season.
Impact in persons aged 15 to 64 years
Data were available for four out of five of the primary
outcomes. There was no clearly identified seasonality in
the pre-vaccine period for the non-specific outcome
measures in this age group (Fig. 3). Moderate reduc-
tions were seen in persons aged 15–64 years across all
outcome measures (Table 2). In the post-vaccine
period, hospitalisations for all-cause AGE fell by 8%
(95% CI 2–14%), ED attendances for gastrointestinal
conditions by 29% (95% CI 16–40), and WIC and GP
consultations for infectious gastroenteritis by 24% (95%
CI 7–38%) and 26% (95% CI 18–33%), respectively.
There were no significant differences in the level of
percentage change on comparing the in-season and
out-of-season periods.
Impact in 65+ year olds
There were significant moderate reductions in all-cause
AGE hospitalisations, ED attendances for gastrointes-
tinal conditions and GP consultations for infectious
gastroenteritis (Fig. 3 and Table 2). The reduction in at-
tendance at WICs for infectious gastroenteritis was non-
significant (47%; 95% CI -15–75%). The absolute rate of
consultations averted was 19 per 10,000 registered popu-
lation for GPs and 34 per 10,000 for WICs (Table 2).
During the rotavirus season, proportional reductions
were slightly higher than out-of-season, although the
difference was not significant.
Vaccine impact by socioeconomic deprivation status
Burden of gastrointestinal infection prior to vaccine
introduction
Prior to vaccine introduction, the risk of being admitted
to hospital for all-cause AGE was 57% higher (IRR =
1.57; 95% CI 1.51–1.64) in the most socioeconomically
deprived populations of Merseyside compared to the
least (Fig. 4). Age-group-stratified analyses showed that
in all age groups apart from those 5–14 years of age
(IRR = 1.08; 95% CI 0.96–1.21), the risk of hospitalisa-
tion with all-cause AGE was significantly greater in the
most socioeconomically deprived populations of Mersey-
side compared to the least. Children < 12 months of age
in the most socioeconomically deprived quintile had
Fig. 3 Trends in four study outcome measures for older children and adults aged 15+ years in Merseyside, UK, July 2008 to June 2016. Each
analysis examines trends, including comparison of observed incidence (blue line) after rotavirus vaccination (July 2013 to June 2016) in the UK
with expected incidence (red line) and associated 95% confidence intervals (red shaded area) in the absence of vaccination. Expected incidence
and 95% confidence intervals are based on predictions from regression models fitted to available historic data for each outcome measure. The
black hashed line represents the introduction of rotavirus vaccine in the UK in July 2013. CI confidence interval, ED emergency department, GP
general practice, WIC walk-in centre
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the highest rate of hospitalisation (47 per 1,000 person
years), compared with 36 per 1,000 person years in the
least deprived (IRR = 1.31; 95% CI 1.16–1.47). Among
12–23-month-olds, the age group with the second
highest rates of hospitalisation, the difference between
the most deprived (30 per 1,000 person years) and least
deprived (26 per 1,000 person years) was less
pronounced (IRR = 1.15; 95% CI 1.01–1.31).
Hospitalisations averted per child vaccinated
We estimated the number of all-cause AGE hospitali-
sations potentially averted in Merseyside due to rota-
virus vaccination in two vaccine-eligible age cohorts,
< 12 months and 12–23 months of age. In children
aged < 12 months living in the most deprived popula-
tions, it was estimated that in 2014/15 and 2015/16,
28 (95% CI 25–31) and 26 (95% CI 23–30) all-cause
AGE hospitalisations were averted per 1,000 first-dose
rotavirus vaccines delivered, respectively. In the least
deprived populations, 15 (95% CI 12–17) and 13 (95%
CI 11–16) all-cause AGE hospitalisations were averted
per 1,000 first-dose rotavirus vaccines delivered in
2014/15 and 2015/16, respectively (Fig. 5). For the
cohort aged 12–23 months, it was estimated that
there were 18 (95% CI 15–20) all-cause AGE hospita-
lisations averted per 1,000 persons vaccinated with at
least one dose of rotavirus vaccine in 2015/16 in the
most deprived populations, and 13 all-cause AGE
hospitalisations averted (95% CI 11–16) in the least
deprived populations.
If the WHO target for primary childhood immunisations
of 95% uptake was attained in each deprivation stratum
nationally (England), 10,811 all-cause AGE hospitalisations
of infants would have been averted in 2015/16, with 41%
(4,395; 95% CI 3,898–4,925) of those averted in the most
deprived population (Table 3). Among 12–23-month-olds,
9,472 all-cause AGE hospitalisations would be expected to
have been averted, with 31% (2,940; 95% CI 2,570–3,330)
of those averted in the most deprived population.
Discussion
In this study, which is one of the few studies to evaluate
the impact of rotavirus vaccine introduction simultan-
eously across all levels of the health-care system in a de-
fined geographic area, we have demonstrated reductions
in gastrointestinal disease burden across all levels of
health-care and across all ages. Reductions were greatest
for the most specific and severe disease outcomes (rota-
virus hospitalisations and AGE hospitalisations) during
the rotavirus season and for the youngest children who
were in vaccine-eligible age groups. Smaller reductions
among older unvaccinated populations suggest herd
Fig. 4 Relative risk of hospitalisation with acute all-cause-gastroenteritis prior to vaccine introduction, by age group and deprivation quintile, July
2004 to June 2013, Merseyside, UK. ref reference
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protection. The impact of vaccination was also greater in
the most socioeconomically deprived populations, despite
lower vaccine coverage.
Most previous studies that evaluated rotavirus vaccine
impact in high-income countries focussed on severe dis-
ease outcomes, with the magnitude of reductions similar
to those described here for children in both vaccine-
eligible and ineligible age groups [12, 29–42]. The
reduction in all-cause AGE of 46% (36–55%) for infants
and 50% (38–60%) for children 12–23 months of age
was also similar to that reported in earlier UK studies, as
was the indication of herd protective effects in older
adults and children [12, 36].
For less severe disease outcomes (people with disease
presenting to GPs and WICs), we demonstrated smaller
relative reductions compared to more specific or severe
Table 3 Predicted all-cause acute gastroenteritis hospitalisations averted nationally in children under 2 years of age in 2015/16 at
95% vaccine uptake
Age group Index of Multiple
Deprivation quintile
Estimated national
population (2016) [16]
Hospitalisations averted at 95% vaccine uptake
Number 95% Lower CI 95% Upper CI
< 12 months 1 (most deprived) 174,784 4395 3898 4925
2 149,462 2185 1795 2603
3 126,372 1597 1292 1924
4/5 (least deprived) 212,359 2634 2156 3147
Total 662,977 10,811
12–23 months 1 (most deprived) 176,129 2941 2579 3330
2 149,862 2397 2080 2740
3 126,517 1363 1124 1621
4/5 (least deprived) 218,485 2771 2359 3218
Total 670,993 9472
CI confidence interval
Fig. 5 Estimated all-cause acute gastroenteritis hospitalisations averted per 1,000 vaccine first doses delivered in the 2014/15 and 2015/16 seasons
for vaccine-eligible cohorts aged < 12 months and 12–23 months. AGE acute gastroenteritis
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disease outcomes. However, these reductions constitute
a substantial contribution to the absolute number of
health-care contacts averted through vaccination. The
impact on non-specific outcome measures was consist-
ently highest during the rotavirus season for children
under 5 years, suggesting that the observed reduction in
incidence of AGE is likely to be due to a real reduction
in incidence of rotavirus disease. The smaller reductions
seen in consultations in primary care (WICs and GPs)
are likely explained by the non-specific gastroenteritis
outcome measure and also because of the presumed
lower effectiveness of rotavirus vaccine against milder
disease [43, 44]. Furthermore, the reductions in GP
consultations for infectious gastroenteritis observed for
children in vaccine-eligible age groups (19% for infants
and 13% for 12–23 months) are epidemiologically plaus-
ible, since a study from the pre-vaccine period estimated
that rotavirus was detected by enzyme-linked immuno-
sorbent assay (ELISA) in 14% and by ELISA and/or PCR
in approximately 19% of infectious intestinal disease
cases seen in GP consultations for UK children under 5
[45, 46], with this estimate likely to be higher in infants.
Furthermore, the estimated reductions in WIC atten-
dances and GP consultations are comparable to that
reported from an analysis of UK syndromic surveillance of
GP consultations for gastroenteritis, diarrhoea and vomit-
ing (26% reduction for infants) [12]. They are also compar-
able with reductions in AGE outpatient attendances
reported in Finland (13% reduction in infants) [33, 47] and
all-cause AGE community clinic visits in Israel (19%
reduction in infants and 16% for 12–23-month-olds) [48].
We have shown that the most deprived populations
were at the greatest risk of all-cause AGE prior to
vaccine introduction, with the highest rates of disease
occurring in infants in the most deprived populations.
This supports previous findings from a lower-resolution
national study, which showed that the rate of
hospitalisation with all-cause AGE increased with in-
creasing deprivation [17]. The uptake of rotavirus vac-
cination in our study population was also associated
with neighbourhood-level deprivation, with a signifi-
cantly lower uptake of the first dose of the vaccine and
lower completion of the full two-dose schedule in the
most deprived populations. Similar findings have been
shown in Merseyside for measles, mumps and rubella
vaccination, and locally and nationally for childhood in-
fluenza vaccination [18, 19].
We were able to overlay a combination of small-area-
level deprivation status, vaccine uptake and all-cause
AGE hospitalisations to estimate the disease averted per
first vaccine dose delivered for different deprivation
strata. In infants, disease averted by vaccination was
higher in the most deprived areas, suggesting that even
with lower vaccine uptake, the most deprived populations
benefit the most from the vaccination programme. The
higher rates of disease averted in infants < 12 months of
age living in the most deprived populations is likely to re-
flect the higher baseline burden of disease in this group
and the relative inequity of hospitalisation rates prior to
vaccine introduction. However, for 12–23-month-olds,
there is a smaller difference in incidence of disease averted
between the least deprived and the most deprived areas,
reflecting the lower baseline inequity in disease burden
between the deprivation strata.
Nationally, there are disproportionately more infants
and young children living in the most deprived quintile
(26%) compared to the least deprived (15%) [15, 16].
With individual-level vaccine effectiveness known to be
lower in persons with a lower socioeconomic status from
studies conducted in high-income settings [49, 50], im-
proving vaccine uptake in the most deprived populations
will have the biggest impact towards reducing rotavirus-
associated disease. We estimate that over 41% of all-
cause AGE hospitalisations averted in infants due to
rotavirus vaccination would be averted in the most de-
prived populations if vaccine uptake was equitable
across deprivation strata at the WHO vaccine uptake
target of 95% [27, 28].
Strengths and limitations
This ecological study using routine health service data is
subject to a number of limitations. There is an inherent
problem with clinical coding of rotavirus gastroenteritis in
UK hospitals. A quality analysis at Alder Hey Children’s
Hospital showed that only 39% of laboratory-confirmed
rotavirus hospitalisations were coded as ICD-10 rotaviral
enteritis (A08.0), and this figure is lower in other UK hos-
pitals [51]. Therefore, in this study, for the RVGE hospital-
isation outcome measure, we used hospitalisations that
were laboratory-confirmed rotavirus from Alder Hey
rather than ICD-10 codes.
In the context of this outcome measure, it is important
to acknowledge the change in rotavirus diagnostic
testing methods that occurred at Alder Hey during the
study period (Table 1). An enzyme immunoassay was
used for 10 of the 14 study years, whilst immuno-
chromatography was utilised between 2005 and 2008.
The immuno-chromatographic method used (VIKIA®,
Rota-Adeno) has a slightly lower diagnostic accuracy
compared to enzyme immunoassay methods [52, 53].
However, the pre-vaccine introduction time series
spanned 11 years, and since the change in testing prac-
tices was not accompanied by a clear non-secular vari-
ation in RVGE hospitalisation rates, we would not
expect this change to have impacted significantly on
effect estimates.
Since rotavirus detection is not routinely undertaken
in community settings, such as GP and WICs,
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syndromic and non-specific outcomes related to gastro-
enteritis were used, and we were, therefore, unable to ac-
count for the contribution of other pathogens causing
AGE. However, the predictable seasonality of rotavirus
infection allowed the analysis to focus on the rotavirus
season, which should improve the robustness of re-
duction estimates in age-eligible children. In older
children and adults, the estimates are more uncer-
tain because there is limited laboratory testing and
surveillance data on rotavirus seasonality and disease
burden in these age groups in the pre-vaccine
period. The lack of routine testing is evidenced by
the recommendation in the Standards for Microbiology
Investigation S7: gastroenteritis and diarrhoea that
rotavirus testing is only standard for sporadic cases of
gastroenteritis under the age of 5 years and immunocom-
promised cases [54].
Because of these limitations, the model fit was less good
for older populations due to the less seasonal and more
random incidence of gastroenteritis disease, and in these
situations the analysis may have overestimated the impact
of vaccination. Furthermore, we used a non-dynamic re-
gression fit and so we did not account for changes in the
force of the infection due to a reduction in the number of
cases. We were, therefore, not able to adjust the predicted
incidence to account for current levels of infection. A full
transmission model would be required to describe fully
the reduction in the transmission rate and associated case
reduction due to vaccination. Despite these limitations,
studies in the UK, Australia, Europe and the US also show
an impact in older populations [12, 36, 37, 42, 55–57].
The number of hospitalisations averted nationally
under a uniform 95% vaccine uptake was made using
two main assumptions. Firstly, that the population of
Merseyside is representative of the national population
and secondly, that the relationship between vaccine
uptake and the herd protective effect of vaccination is
linear. Therefore, the estimates are likely to be con-
servative as a consequence of assuming a linear rela-
tionship, particularly if the level of rotavirus vaccine
uptake required for population protection is reached
before 95% uptake.
Finally, the novelty of measuring vaccine impact on
multiple levels of a health system simultaneously in a
defined population provides robustness that any de-
tected changes are due to rotavirus vaccination rather
than idiosyncrasies of one particular data set. For
example, we detected delayed peak activity (April/May)
in children aged 24–59 months across all outcome mea-
sures in season 2014/15, strengthening the evidence that
the data sets used in this study were useful in detecting
rotavirus activity in non-specific outcomes. This delayed
peak is also observed in laboratory-confirmed rotavirus
detections nationally.
Conclusion
This analysis identified the effect of rotavirus vaccination
on health-care utilisation for acute gastroenteritis in the
four major levels of the UK health system for five out-
comes of varying specificity. The study strongly indicates
that rotavirus vaccination has reduced the incidence of
acute gastroenteritis across the health-care system in both
vaccine-eligible and ineligible populations. Rotavirus vac-
cination will, therefore, contribute to alleviating the
increasing pressures on acute services across a health sys-
tem. With an impact greater than that predicted through
cost-effective modelling in the UK [58], these data strongly
support the sustained use of the vaccine in the UK and
continued expansion to other European countries.
We have also shown that prioritising vaccine uptake in
the most socioeconomically deprived communities is
likely to give the greatest health benefit in terms of
population disease burden and can contribute to redu-
cing health inequalities. Further studies are required to
disentangle which factors related to socioeconomic
deprivation have the greatest influence on vaccine
acceptance, so that interventions to improve vaccine
uptake can be targeted effectively.
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